Open AccessPB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN
Author(s) -
Pemmaraju N.,
Martinelli G.,
Todisco E.,
Tarella C.,
Montesinos P.,
Lane A. A.,
Erba H. P.,
Sweet K. L.,
Walter R. B.,
Deconinck E.,
Wang E. S.,
Aribi A.,
Ulrikson M. L.,
Levy M. Y.,
Lebon D.,
Marconi G.,
DeAngelo D. J.,
Rizzieri D.,
Konopleva M.,
Sloss C. M.,
Wang J.,
Malcolm K. A.,
ZweidlerMcKay P. A.,
Daver N. G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850164.28901.b2
Subject(s) - medicine , myeloid leukemia , tolerability , interleukin 3 receptor , hematology , haematopoiesis , oncology , adverse effect , stem cell , biology , genetics